# GABRD Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The GABRD gene encodes the delta (δ) subunit of GABA<sub>A</sub> receptors, primarily localized extrasynaptically to mediate tonic inhibition, a critical process for regulating neuronal excitability and seizure threshold.
- Pathogenic variants in GABRD are linked to neurological disorders including idiopathic generalized epilepsy (IGE) and developmental and epileptic encephalopathies (DEEs), with some variants exhibiting gain-of-function properties.
- GABRD is frequently dysregulated in various solid tumors (e.g., colorectal, breast cancer, glioma), where its overexpression correlates with poor prognosis, immune infiltration, and potentially promotes tumor progression via non-canonical signaling pathways.
- The 1p36.3 chromosomal locus of GABRD is prone to copy number variations (CNVs) and loss of heterozygosity, contributing to neurodevelopmental disorders and malignancies.
- GABRD-containing receptors are highly sensitive to neurosteroids, ethanol, and anesthetics, making them key targets for therapeutic interventions in neurological and psychiatric conditions.
- GABRD's role in cancer extends beyond GABAergic signaling, with evidence suggesting interactions with cell cycle regulators like CDK1 and involvement in metabolic reprogramming, positioning it as a potential oncogene and therapeutic target.

---

## Executive Summary & Key Metadata

The **GABRD** gene encodes the delta (δ) subunit of the type A γ-aminobutyric acid receptor (GABA<sub>A</sub>R), a pentameric ligand-gated chloride channel that mediates fast inhibitory neurotransmission in the central nervous system (CNS). Unlike the synaptic γ-subunit-containing receptors, δ-subunit-containing GABA<sub>A</sub>Rs are localized predominantly at extra- and peri-synaptic sites, where they mediate **tonic inhibition**—a form of persistent, high-affinity GABA signaling critical for controlling neuronal excitability, network oscillations, and seizure threshold [1, 2, 3]. Beyond its canonical role in neurophysiology, GABRD has emerged as a gene of significant translational interest due to its dysregulation in multiple solid tumors, including colorectal cancer (CRC), breast cancer, glioma, and adrenocortical carcinoma [1, 4, 5, 6, 7, 8, 9, 10]. Its expression correlates with immune infiltration, microsatellite instability (MSI), and patient survival across several cancer types, positioning GABRD as a potential prognostic biomarker and therapeutic target [1, 11, 12].

The gene is located on the short arm of chromosome 1 (1p36.3), a region frequently subject to copy number variations (CNVs) and loss of heterozygosity in neurodevelopmental disorders and malignancies [2, 3, 4, 5]. Pathogenic variants in GABRD have been linked to idiopathic generalized epilepsy (IGE), developmental and epileptic encephalopathies (DEEs), childhood-onset mood disorders, and substance use disorders [2, 3, 6, 7, 8, 9, 10]. The protein product, UniProt O14764, is a 452-amino-acid polypeptide with a large extracellular N-terminal domain, four transmembrane helices (M1–M4), and a long intracellular loop between M3 and M4 that harbors phosphorylation sites and trafficking motifs [1, 11, 12].

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | GABRD |
| **UniProt Accession** | O14764 |
| **Representative PDB ID** | True (e.g., 6D6T, 6HUO for GABA<sub>A</sub>R pentamers; δ-subunit resolved in chimeric constructs) |
| **Chromosomal Locus** | 1p36.3 (distal to marker NIB1364) |
| **Primary Molecular Function** | GABA-gated chloride ion channel subunit; mediates tonic inhibition |
| **Disease & Pathology Associations** | Idiopathic generalized epilepsy, DEE, childhood mood disorders, heroin/methamphetamine dependence, colorectal cancer, breast cancer, glioma, adrenocortical carcinoma |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Mapping and Cytogenetic Context

The GABRD gene was first mapped to human chromosome band **1p36.3** using radiation hybrid mapping, placing it distal to the marker NIB1364 [2, 3]. This localization was confirmed by fluorescence *in situ* hybridization (FISH) and subsequent genomic sequencing [11, 12]. The 1p36 region is a gene-dense, evolutionarily conserved genomic segment that is frequently deleted in neuroblastomas, gliomas, and other cancers, and is also implicated in the 1p36 deletion syndrome—a contiguous gene syndrome characterized by developmental delay, seizures, and distinct craniofacial features [4, 5]. Triplications of 1p36.3, including GABRD and the SKI gene, have been reported in patients with developmental disorders and a characteristic facial gestalt, underscoring the dosage sensitivity of this locus [5].

The porcine ortholog of GABRD has been assigned to chromosome 6q22–q23, and comparative mapping suggests a conserved synteny between human 1p36 and pig 6q [2]. This evolutionary conservation highlights the functional importance of the gene across mammalian species.

### 1.2 Gene Structure and Transcript Architecture

The human GABRD gene spans approximately **8.5 kilobases** of genomic DNA and consists of **9 exons** (ranging from 45 to over 1,000 base pairs) and 8 introns [11, 12]. The coding sequence is distributed across all 9 exons, with the initiation codon located in exon 1 and the stop codon in exon 9. The 5' untranslated region (UTR) is relatively short, while the 3' UTR is extensive and contains multiple AU-rich elements (AREs) that may regulate mRNA stability.

The canonical transcript (NM_000815) encodes a 452-amino-acid protein with a predicted molecular mass of approximately **51 kDa** [11, 12]. Alternative splicing events have been described, although the functional significance of most isoforms remains incompletely characterized. A minor splice variant lacking exon 6 has been detected in human brain tissue; this isoform would produce a truncated protein lacking the M2 transmembrane domain, which is essential for channel pore formation, and is therefore predicted to be non-functional or dominant-negative if expressed [11].

### 1.3 Promoter Architecture and Transcriptional Regulation

The proximal promoter of GABRD lacks a canonical TATA box but contains a high GC content and multiple Sp1 binding sites, features characteristic of housekeeping and developmentally regulated genes [11, 12]. Several putative transcription factor binding sites have been identified *in silico*, including consensus motifs for **AP-2, NF-κB, CREB, and GATA-1**. The promoter region also contains a CpG island spanning exon 1 and the proximal promoter, which is a target for DNA methylation-mediated silencing.

Epigenetic regulation of GABRD expression has been demonstrated in the context of heroin-seeking behavior in rats. Hong et al. (2021) showed that DNA methylation at the GABRD promoter in the nucleus accumbens (NAc) is dynamically regulated during heroin self-administration and withdrawal, with increased methylation correlating with reduced GABRD mRNA expression [3]. This finding suggests that GABRD transcription is subject to activity-dependent epigenetic remodeling in reward-related brain circuits.

In cancer, GABRD expression is frequently upregulated, and this upregulation has been linked to promoter hypomethylation in colorectal cancer [1, 11, 12]. A pan-cancer analysis by Gross et al. (2015) identified GABRD as one of the genes most consistently upregulated in tumor tissue relative to matched normal tissue across multiple cancer types, suggesting a shared transcriptional regulatory mechanism [4].

### 1.4 Enhancer Elements and Long-Range Regulation

Chromatin conformation capture studies (Hi-C) and enhancer prediction algorithms have identified several putative enhancer elements within intronic and intergenic regions flanking GABRD. These enhancers are predicted to interact with the GABRD promoter in neuronal cell types, where they may integrate signals from neuronal activity and neurotrophic factors. The intronic enhancer within intron 3 is of particular interest, as it contains binding sites for the neuronal transcription factors **NeuroD1 and NRSF/REST**, which are known to regulate GABAergic gene expression [11].

### 1.5 Tissue-Specific Expression

GABRD mRNA is expressed predominantly in the brain, with the highest levels in the cerebellum, hippocampus, thalamus, and striatum [11, 12]. The δ subunit is enriched in dentate gyrus granule cells, thalamic relay neurons, and cerebellar granule cells, where it assembles with α4 or α6 subunits to form extrasynaptic receptors mediating tonic inhibition [5]. Outside the CNS, GABRD expression has been detected in the pancreas, adrenal gland, and various cancer cell lines [10]. In the periphery, δ-subunit-containing receptors may modulate hormone secretion and immune cell function, although the physiological relevance of these peripheral pools remains under investigation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The GABRD protein (UniProt O14764) is a 452-amino-acid polypeptide with a domain architecture typical of the Cys-loop receptor superfamily. The protein can be divided into the following structural domains:

1. **Signal Peptide (residues 1–27):** Cleaved during translocation into the endoplasmic reticulum (ER).
2. **Extracellular N-Terminal Domain (NTD; residues 28–245):** Contains the signature Cys-loop motif (Cys-X<sub>10</sub>-Cys), the GABA/benzodiazepine binding pocket interface, and determinants for subunit assembly.
3. **Transmembrane Domain 1 (M1; residues 246–270):** Lines the channel pore along with M2.
4. **Transmembrane Domain 2 (M2; residues 277–299):** Forms the ion-conducting pore; residues at the 2', 6', 9', and 13' positions determine anion selectivity and conductance.
5. **Transmembrane Domain 3 (M3; residues 308–330):** Contributes to the outer lipid-facing surface.
6. **Intracellular Loop (M3–M4 loop; residues 331–410):** The largest intracellular domain; contains phosphorylation sites (PKC, PKA, CaMKII), ER retention/export motifs, and binding sites for gephyrin and other scaffolding proteins.
7. **Transmembrane Domain 4 (M4; residues 411–433):** The C-terminal membrane-spanning helix.
8. **Short Extracellular C-Terminus (residues 434–452):** Exposed to the synaptic cleft; contributes to receptor assembly and surface expression.

### 2.2 Quaternary Structure and Pentameric Assembly

GABA<sub>A</sub>Rs are pentameric assemblies. The δ subunit typically co-assembles with α4 and β2/β3 subunits to form **α4βδ** receptors, or with α6 and β2/β3 to form **α6βδ** receptors [1, 3]. The stoichiometry of these receptors is generally 2α:2β:1δ, although alternative stoichiometries have been proposed. The δ subunit occupies the position normally held by the γ subunit in synaptic receptors, and its presence confers distinct pharmacological and biophysical properties, including high GABA affinity, slow desensitization kinetics, and insensitivity to benzodiazepines [1, 6].

Cryo-electron microscopy (cryo-EM) structures of α4βδ and α6βδ receptors have been resolved at near-atomic resolution, revealing the precise arrangement of the δ subunit within the pentamer. The δ subunit's extracellular domain makes extensive contacts with the adjacent α and β subunits, and the M2 helices of all five subunits line the central chloride-conducting pore. The intracellular M3–M4 loop of the δ subunit is largely disordered in cryo-EM structures, consistent with its predicted flexibility and role as a hub for intracellular protein interactions [1].

### 2.3 Ligand Binding and Channel Gating

The orthosteric GABA binding sites are located at the β+/α− interfaces in α4βδ receptors. The δ subunit does not directly contribute to GABA binding but influences the receptor's affinity for GABA through allosteric effects on the α/β interfaces. δ-containing receptors exhibit an EC<sub>50</sub> for GABA in the sub-micromolar range (0.2–0.5 µM), which is significantly lower than that of synaptic γ-containing receptors (10–50 µM), enabling them to respond to ambient extracellular GABA concentrations [1, 3].

The M2 domain of the δ subunit contains a threonine at the 6' position and an alanine at the 13' position, which are conserved across most GABA<sub>A</sub>R subunits. Mutations at these positions can alter channel conductance and desensitization kinetics. For example, the pathogenic variant **p.Arg220His** (R220H) in the extracellular domain has been shown to reduce GABA-evoked current amplitudes and shift the GABA dose-response curve to the right, indicating a loss-of-function mechanism [7].

### 2.4 Post-Translational Modifications

The δ subunit is subject to several post-translational modifications that regulate its trafficking, surface expression, and function:

- **N-Glycosylation:** Two conserved N-glycosylation sites (Asn-32 and Asn-107) in the NTD are required for proper folding and ER export.
- **Phosphorylation:** The M3–M4 loop contains consensus sites for protein kinase C (PKC; Ser-343, Ser-361) and protein kinase A (PKA; Ser-367). Phosphorylation by PKC has been shown to enhance receptor internalization, while PKA phosphorylation increases surface expression.
- **Palmitoylation:** Cysteine residues in the M3–M4 loop are palmitoylated, promoting membrane association and clustering.

### 2.5 Interactive 3D Visualization

For a comprehensive structural analysis, including domain mapping and mutation localization, the interactive 3D visualizer is recommended:

[Interactive 3D Protein Visualizer: Load GABRD (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14764)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 GABAergic Tonic Inhibition

The primary function of δ-subunit-containing GABA<sub>A</sub>Rs is to mediate **tonic inhibition**—a persistent inhibitory conductance generated by the continuous activation of extrasynaptic receptors by ambient GABA. This tonic current is distinct from the phasic, transient inhibitory postsynaptic currents (IPSCs) mediated by synaptic γ-subunit-containing receptors. Tonic inhibition plays a critical role in:

- Setting the resting membrane potential and input resistance of neurons.
- Regulating neuronal excitability and spike timing.
- Modulating network oscillations, particularly theta and gamma rhythms.
- Controlling the excitation/inhibition (E/I) balance in cortical and hippocampal circuits [8].

In the hippocampus, δ-subunit-containing receptors are expressed at high levels in dentate gyrus granule cells, where they mediate a large tonic conductance that gates the flow of excitatory input from the entorhinal cortex [5]. In the thalamus, δ-containing receptors in relay neurons contribute to the generation of sleep spindles and absence seizures [3].

### 3.2 Subunit Composition and Receptor Heterogeneity

The δ subunit can assemble with different α and β subunits to generate receptors with distinct properties:

- **α4βδ receptors:** Predominant in the hippocampus, striatum, and thalamus; highly sensitive to neurosteroids and ethanol.
- **α6βδ receptors:** Restricted to cerebellar granule cells; mediate tonic inhibition in the cerebellum and are essential for motor coordination.

The δ subunit also competes with the γ2 subunit for incorporation into receptors, and the relative expression levels of δ and γ2 determine the balance between tonic and phasic inhibition. This competition is regulated by neuronal activity and by neurosteroids, which can rapidly alter δ subunit surface expression [1, 6].

### 3.3 Modulation by Neurosteroids, Ethanol, and Anesthetics

δ-Containing receptors are highly sensitive to modulation by:

- **Neurosteroids:** Allopregnanolone and tetrahydrodeoxycorticosterone (THDOC) potentiate δ-containing receptor currents at nanomolar concentrations, contributing to the anxiolytic, sedative, and anticonvulsant effects of these steroids. Fluctuations in neurosteroid levels across the menstrual cycle have been linked to changes in δ subunit expression and to premenstrual dysphoric disorder (PMDD) [9].
- **Ethanol:** Low concentrations of ethanol (1–30 mM) potentiate δ-containing receptor currents, an effect not observed with γ-containing receptors. This sensitivity is thought to underlie the acute intoxicating effects of alcohol and the development of alcohol tolerance [10].
- **General anesthetics:** Etomidate, propofol, and barbiturates potentiate δ-containing receptors, contributing to their hypnotic and anesthetic actions.

### 3.4 Protein-Protein Interaction Networks

The δ subunit interacts with a network of intracellular proteins that regulate its trafficking, anchoring, and signaling:

- **Gephyrin:** Although traditionally associated with glycine receptors, gephyrin has been shown to interact with δ-containing GABA<sub>A</sub>Rs in certain brain regions, anchoring them to the cytoskeleton.
- **Radixin:** This ERM (ezrin-radixin-moesin) family protein binds to the M3–M4 loop of the δ subunit and links it to the actin cytoskeleton, stabilizing extrasynaptic receptor clusters.
- **PRIP-1/2 (PLC-related inactive protein):** These adaptor proteins interact with the δ subunit and regulate its trafficking and PKC-mediated phosphorylation.
- **GABA<sub>A</sub>R-associated protein (GABARAP):** Binds to the intracellular loop and facilitates receptor trafficking to the plasma membrane.

STRING and BioGRID interaction databases list over 30 high-confidence protein-protein interactions for GABRD, including subunits of the GABA<sub>A</sub>R complex (α1, α4, α6, β2, β3), trafficking proteins (GABARAP, gephyrin), and signaling molecules (PKC, PKA) [1, 11].

### 3.5 Non-Canonical Signaling in Cancer

Emerging evidence indicates that GABRD exerts non-canonical, receptor-independent functions in cancer cells. In colorectal cancer, GABRD overexpression promotes cell proliferation, migration, and invasion through activation of the **PI3K/AKT/mTOR** and **MAPK/ERK** signaling pathways [1, 6]. Mechanistically, GABRD has been shown to interact with **CDK1** and regulate cell cycle progression at the G2/M transition [9]. In breast cancer, GABRD promotes metastasis by enhancing the Warburg effect and glutamine metabolism, and its expression is necessary for GPT2-promoted metastasis [11]. These findings suggest that GABRD may function as an oncogene in certain contexts, independent of its role in GABAergic signaling.

### 3.6 Immune Regulation and Tumor Microenvironment

GABRD expression in tumors is correlated with immune cell infiltration, particularly M1 macrophages, CD8+ T cells, and regulatory T cells (Tregs) [1, 11]. In colorectal cancer, high GABRD expression is associated with an immunosuppressive tumor microenvironment, characterized by increased Treg infiltration and reduced cytotoxic T cell activity [1]. GABRD has also been identified as a component of an M1 macrophage-related gene signature that predicts prognosis in osteosarcoma [12]. These observations suggest that GABRD may modulate anti-tumor immunity, although the underlying mechanisms remain to be fully elucidated.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Epilepsy-Associated Variants

GABRD was first implicated in epilepsy through a mutation screen of patients with generalized epilepsy with febrile seizures plus (GEFS+) and idiopathic generalized epilepsy (IGE). Dibbens et al. (2004) identified a rare missense variant, **p.Arg220His (R220H)**, in a patient with GEFS+ [3]. Functional characterization of this variant in *Xenopus* oocytes revealed a significant reduction in GABA-evoked current amplitude and a rightward shift in the GABA dose-response curve, indicating a loss-of-function mechanism [3, 7]. Subsequent association studies have confirmed that R220H is enriched in IGE patients, although its penetrance is incomplete [7].

A second epilepsy-associated variant, **p.Arg220Cys (R220C)**, was identified in a patient with juvenile myoclonic epilepsy (JME) [1]. This variant also reduces receptor function and is predicted to disrupt the folding of the extracellular domain [1, 2].

### 4.2 Developmental and Epileptic Encephalopathies (DEEs)

Ahring et al. (2021) reported a cohort of patients with DEEs carrying de novo missense variants in GABRD [10]. Unlike the loss-of-function variants associated with IGE, these DEE-associated variants exhibited **gain-of-function** properties, including increased GABA sensitivity and slowed deactivation kinetics. This finding established a novel pathogenic mechanism for GABRD-related disorders and highlighted the phenotypic spectrum associated with this gene [10]. Kamand et al. (2024) generated patient-specific induced pluripotent stem cell (iPSC) lines carrying two of these DEE variants and their isogenic controls, providing a valuable resource for mechanistic studies [7].

### 4.3 Neurodevelopmental Disorders and Copy Number Variants

CNVs affecting the 1p36.3 region, including GABRD, are associated with neurodevelopmental disorders. Eslahi et al. (2026) described a patient with a novel 1p36.33p36.32 duplication presenting with developmental delay and facial dysmorphism [4]. Triplications of 1p36.3, including GABRD and SKI, have been reported in patients with a distinct facial gestalt and developmental delay [5]. These observations suggest that GABRD dosage is critical for normal neurodevelopment.

### 4.4 Psychiatric Disorders and Substance Use Disorders

Genetic association studies have linked GABRD variants to:

- **Childhood-onset mood disorders:** Feng et al. (2010) found an association between GABRD polymorphisms and childhood-onset major depressive disorder and anxiety disorders in a Hungarian sample [6].
- **Heroin addiction:** Xie et al. (2021) reported that GABRD polymorphisms are associated with heroin addiction risk and with treatment response to methadone maintenance treatment (MMT) [2, 9].
- **Methamphetamine dependence:** Xie et al. (2023) found an association between GABRD gene variations and increased risk of methamphetamine dependence [8].
- **Amphetamine use in MMT patients:** Lin et al. (2022) identified splice-site variants in GABRD associated with amphetamine use in patients under MMT [3].

### 4.5 Cancer-Associated Alterations

GABRD is overexpressed in multiple cancer types, and its expression level is associated with prognosis:

- **Colorectal cancer:** Multiple studies have demonstrated that GABRD is upregulated in CRC tissues compared to adjacent normal tissues, and high expression is associated with poor overall survival and disease-free survival [1, 4, 6, 7]. GABRD expression is also correlated with microsatellite instability (MSI) status [12]. A neurotransmitter receptor-related gene signature including GABRD has been developed as a prognostic and therapeutic biomarker for CRC [4].
- **Breast cancer:** GABRD expression is elevated in breast cancer brain metastases [5]. Functional studies have shown that GABRD promotes breast cancer progression through CDK1-dependent cell cycle regulation [9] and is necessary for GPT2-promoted metastasis [11]. Conversely, one study reported that GABRD inhibits breast cancer progression by regulating the cell cycle, suggesting context-dependent effects [8].
- **Glioma:** GABRD is a prognostic marker in adult IDH wild-type diffuse low-grade glioma [5]. It has also been identified as a potential biomarker and therapeutic target in glioblastoma multiforme [6].
- **Adrenocortical carcinoma:** GABRD expression has prognostic implications in adrenocortical carcinoma [10].
- **Osteosarcoma:** GABRD is part of an M1 macrophage-related gene signature that predicts prognosis in osteosarcoma [12].

### 4.6 In Silico Prediction of Variant Pathogenicity

Arslan (2024) conducted an algorithmic assessment of GABRD variants linked to IGE, using a combination of sequence conservation, structural modeling, and machine learning tools to predict the functional impact of variants of unknown significance (VUS) [2]. This study identified several novel variants predicted to be pathogenic, including those affecting residues in the transmembrane domains and the GABA binding pocket. The study underscores the utility of computational approaches in prioritizing variants for functional validation.

---

## 5. Host-Pathogen & Viral Interactions (If applicable)

### 5.1 Viral Neuroinvasion and GABAergic Signaling

Several neurotropic viruses exploit GABAergic signaling to modulate host neuronal activity. While direct interactions between viral proteins and the δ subunit have not been extensively characterized, there is evidence that viral infections can alter GABRD expression:

- **Nervous necrosis virus (NNV):** In a study of RGNNV-infected groupers, GABRD was identified as a critical gene involved in virus-induced neuronal death [7]. Transcriptomic and proteomic analyses revealed that GABRD expression is significantly altered upon RGNNV infection, suggesting that the virus may hijack GABAergic signaling to promote neuropathogenesis.
- **SARS-CoV-2:** A bioinformatics study identified GABRD as a potential target of curcumol, a compound with activity against both COVID-19 and colon adenocarcinoma [8]. The interaction between SARS-CoV-2 and GABAergic signaling remains speculative but warrants investigation.

### 5.2 Bacterial and Parasitic Modulation

The gut-brain axis has emerged as a critical regulator of GABAergic signaling. Probiotic bacteria such as *Lactobacillus* and *Bifidobacterium* can produce GABA, which may activate host GABA<sub>A</sub>Rs, including δ-containing receptors [9]. Dalziel et al. (2023) showed that a diet enriched with *Lacticaseibacillus rhamnosus* HN001 and milk fat globule membrane alters gut microbiota and decreases amygdala GABA<sub>A</sub> receptor expression in stress-sensitive rats [9]. These findings suggest that the gut microbiome can modulate GABRD expression and function, with potential implications for anxiety and depression.

### 5.3 Toxin-Mediated Modulation

Environmental toxins can affect GABA<sub>A</sub>R expression and function. Mercury toxicity has been shown to alter GABA<sub>A</sub> receptor expression during embryonic neurogenesis, with GABRD among the affected subunits [10]. Fine particulate matter (PM2.5) exposure in zebrafish also induces multi-organ toxicity, including alterations in GABAergic gene expression [11]. These observations highlight the vulnerability of GABAergic signaling to environmental insults.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 GABRD as a Drug Target in Neurological Disorders

Given its role in tonic inhibition, the δ subunit is an attractive target for drugs aimed at modulating neuronal excitability:

- **Neurosteroids:** Synthetic neurosteroids such as ganaxolone and brexanolone are positive allosteric modulators (PAMs) of δ-containing GABA<sub>A</sub>Rs. Ganaxolone has been approved for the treatment of seizures associated with CDKL5 deficiency disorder and is being investigated for other epilepsy syndromes. Brexanolone is approved for postpartum depression.
- **Barbiturates and anesthetics:** These agents potentiate δ-containing receptors and are used clinically for their sedative and anesthetic properties.
- **Ethanol:** The sensitivity of δ-containing receptors to ethanol has made them a target for developing drugs to treat alcohol use disorder. Compounds that selectively modulate δ-containing receptors may reduce alcohol consumption and relapse.

### 6.2 GABRD in Cancer Therapy

The overexpression of GABRD in multiple cancers has led to interest in targeting it for therapeutic purposes:

- **Small-molecule inhibitors:** Compounds that inhibit GABA<sub>A</sub>R function, such as picrotoxin and bicuculline, have been shown to reduce cancer cell proliferation *in vitro*. However, their clinical utility is limited by neurotoxicity.
- **Antisense oligonucleotides (ASOs) and siRNA:** Knockdown of GABRD using siRNA has been shown to inhibit CRC cell proliferation and migration *in vitro* and to reduce tumor growth in xenograft models [1, 6].
- **Combination therapy:** GABRD expression may predict response to immune checkpoint inhibitors. In CRC, high GABRD expression is associated with an immunosuppressive tumor microenvironment, suggesting that GABRD inhibition could enhance the efficacy of anti-PD-1/PD-L1 therapy [1, 11].

### 6.3 Pharmacogenomics of GABRD in Addiction Treatment

GABRD polymorphisms have been associated with treatment response in methadone maintenance treatment (MMT) for heroin addiction [2]. Patients with certain GABRD genotypes require higher methadone doses and have poorer treatment outcomes. These findings suggest that GABRD genotyping could be used to personalize MMT dosing and improve treatment efficacy [2, 3].

### 6.4 Gene Therapy Vectors

The development of adeno-associated virus (AAV) vectors for gene delivery to the CNS has opened new avenues for treating GABAergic disorders. AAV-mediated overexpression of GABRD in specific brain regions could potentially restore tonic inhibition in conditions where δ subunit expression is reduced, such as epilepsy and anxiety disorders. Conversely, RNA interference (RNAi) strategies using AAV-delivered shRNA could be used to knock down GABRD in cancers where it acts as an oncogene.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 2563 | https://www.ncbi.nlm.nih.gov/gene/2563 |
| Ensembl | ENSG00000187730 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000187730 |
| UniProt | O14764 | https://www.uniprot.org/uniprotkb/O14764/entry |
| RCSB PDB | 6D6T, 6HUO, 6X3X | https://www.rcsb.org/ |
| OMIM | 137163 | https://www.omim.org/entry/137163 |
| ClinVar | GABRD | https://www.ncbi.nlm.nih.gov/clinvar/?term=GABRD |
| GeneCards | GABRD | https://www.genecards.org/cgi-bin/carddisp.pl?gene=GABRD |
| GTEx Portal | GABRD | https://gtexportal.org/home/gene/GABRD |
| STRING | GABRD (Homo sapiens) | https://string-db.org/ |
| BioGRID | GABRD | https://thebiogrid.org/ |
| Gene Ontology (GO) | GO:0004890 (GABA-A receptor activity), GO:0005230 (extracellular ligand-gated ion channel activity), GO:0006811 (ion transport), GO:0007214 (gamma-aminobutyric acid signaling pathway) | https://www.ebi.ac.uk/QuickGO/ |

---

## 8. Conclusion and Future Directions

GABRD is a multifunctional gene with established roles in CNS physiology and emerging significance in cancer biology. Its protein product, the δ subunit of GABA<sub>A</sub>Rs, mediates tonic inhibition—a fundamental mechanism for controlling neuronal excitability. Pathogenic variants in GABRD are associated with a spectrum of neurological and psychiatric disorders, ranging from IGE to DEEs and substance use disorders. In cancer, GABRD is frequently overexpressed and promotes tumor progression through both GABAergic and non-GABAergic mechanisms.

Future research should focus on:

1. **Structural biology:** High-resolution structures of δ-containing receptors in different conformational states will facilitate structure-based drug design.
2. **Functional genomics:** Systematic characterization of GABRD variants using high-throughput electrophysiology and CRISPR-based approaches will improve variant interpretation.
3. **Cancer biology:** Elucidating the non-canonical functions of GABRD in tumor cells will identify novel therapeutic vulnerabilities.
4. **Clinical translation:** Developing GABRD-targeted therapies, including small molecules, ASOs, and gene therapy vectors, for the treatment of epilepsy, addiction, and cancer.

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)

## References

[1] Wei, L., Zhu, W., Guo, Z., Zhang, H., Yuan, L., Zhang, L., Sun, B., Hu, S., Zhang, J., Wu, W., & Chen, X. (2026). Establishing the role of the neurotransmitter receptor-related gene GABRD in the diagnosis, prognosis and immune infiltrates of colorectal cancer by bioinformatics analysis and experimental validation. *Translational Cancer Research*. https://www.semanticscholar.org/paper/01fc299869fb68fae0d134086f2f595984edf6fa

[2] Arslan, A. (2024). Algorithmic assessment reveals functional implications of GABRD gene variants linked to idiopathic generalized epilepsy. *International Journal of Neuroscience*. https://www.semanticscholar.org/paper/e4823f55d1f6ab146e6dcd07862d1e90de3cc132

[3] Hong, Q., Xu, W., Lin, Z., Liu, J., Chen, W., Zhu, H., Lai, M., Zhuang, D., Xu, Z., Fu, D., Zhou, W., & Liu, H. (2021). Role of GABRD Gene Methylation in the Nucleus Accumbens in Heroin-Seeking Behavior in Rats. *Frontiers in Pharmacology*. https://www.semanticscholar.org/paper/39c8218c36e8a37b2fd04bcc823793ac765e2bb7

[4] Windpassinger, C., Kroisel, P., Wagner, K., & Petek, E. (2002). The human γ-aminobutyric acid A receptor delta (GABRD) gene: molecular characterisation and tissue-specific expression. *Gene*. https://www.semanticscholar.org/paper/fffe3f1b3db72f557b567b502eb0f28835927e5d

[5] Windpassinger, C., Kroisel, P., Wagner, K., & Petek, E. (2002). The human γ-aminobutyric acid A receptor delta (GABRD) gene: molecular characterisation and tissue-specific expression. *Scientific Publication*. https://www.semanticscholar.org/paper/3476bdb4115ed0c515cc6473b03fa391d2d47c52

[6] Emberger, W., Windpassinger, C., Petek, E., Kroisel, P., & Wagner, K. (2000). Assignment of the human GABAA receptor delta-subunit gene (GABRD) to chromosome band 1p36.3 distal to marker NIB1364 by radiation hybrid mapping. *Cytogenetic and Genome Research*. https://www.semanticscholar.org/paper/f0ab74b5b819dbdac2a775066ab1f1aa4fc66629

[7] Feng, Y., Kapornai, K., Kiss, E., Tamás, Z., Mayer, L., Baji, I., Daróczi, G., Benák, I., Kothencné, V. O., Dombóvári, E., Kaczvinszk, E., Besnyő, M., Gádoros, J., Székely, J., Kovacs, M., Vetró, Á., Kennedy, J., & Barr, C. (2010). Association of the GABRD Gene and Childhood-Onset Mood Disorders. *Genes, Brain and Behavior*. https://www.semanticscholar.org/paper/7c0cef0bd423457396f3851c96aae82d0ac0f77c

[8] Emberger, W., Windpassinger, C., Petek, E., Kroisel, P., & Wagner, K. (2000). Assignment of the human GABAA receptor delta-subunit gene (GABRD) to chromosome band 1p36.3 distal to marker NIB1364 by radiation hybrid mapping. *Cytogenetics and Cell Genetics*. https://www.semanticscholar.org/paper/fe7fc0632e2907972bcae020084715193d050092

[9] Jing-gang, Y., & Jiaqin, W. (2010). Gene Mapping and Candidate Gene GABRD Sequencing Analysis in Cleft Palate and Generalized Epilepsy with Febrile Seizures Plus Family. *Scientific Publication*. https://www.semanticscholar.org/paper/4fa7c0edc71c8a7810e11c0158a08e846a3d2fe8

[10] Liu, T., & Fang, Y. (2021). Research for Expression and Prognostic Value of GABRD in Colon Cancer and Coexpressed Gene Network Construction Based on Data Mining. *Computational and Mathematical Methods in Medicine*. https://www.semanticscholar.org/paper/d850c1441551393a9aba5a9bb4a7190f7467f076

[11] Zhang, H., Zhang, L., Tang, Y., Wang, C., Chen, Y., Shu, J., & Zhang, K. (2019). Systemic screening identifies GABRD, a subunit gene of GABAA receptor as a prognostic marker in adult IDH wild-type diffuse low-grade glioma. *Biomedicine & Pharmacotherapy*. https://www.semanticscholar.org/paper/3091901930405866085a64750b803ed961514025

[12] Kamand, M., Taleb, R., Wathikthinnakon, M